Bibliography
- Nevitt GJ, Hutchinson PE. Psoriasis in the community: Prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol 1996;135(4):533-7
- Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352(18):1899-912
- Gordon KB, Ruderman EM. Psoriasis and psoriatic arthritis: an integrated approach. Berlin, New York: Springer; 2005
- Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica 1974;148(1):1-18
- Kaur I, Handa S, Kumar B. Natural history of psoriasis: a study from the Indian subcontinent. J Dermatol 1997;24(4):230-4
- Larsen FS, Hanifin JM. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am 2002;22(1):1-24
- Leung DY, Bieber T. Atopic dermatitis. Lancet 2003;361(9352):151-60
- Bieber T. Atopic dermatitis. N Engl J Med 2008;358(14):1483-94
- Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2007;156(2):203-21
- Ellis C, Luger T, Abeck D, et al. International consensus conference on atopic dermatitis II (ICCAD II*): clinical update and current treatment strategies. Br J Dermatol 2003;148:3-10
- Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol 2006;55(4):607-13
- Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: Results of a 1998 national psoriasis foundation patient-membership survey. Arch Dermatol 2001;137(3):280-4
- Walker MH. A hydrocortisone-pantothenylol aerosol foam for skin therapy. J Am Podiatry Assoc 1962;52:198-202
- Olux-e (clobetasol propionate) foam, 0.05% promotional website. Steiffel Corporation, Palo Alto, CA. Available from: www.olux-e.com [Last accessed 11 February 2008]
- Stein L. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J Am Acad Dermatol 2005;53(1 Suppl 1):S39-49
- Olux-e (clobetasol propionate) foam, 0.05% [package insert]. Steiffel Corporation, Palo Alto, CA, USA; 2007
- Watsky KL, Freije L, Leneveu MC, et al. Water-in-oil emollients as steroid-sparing adjunctive therapy in the treatment of psoriasis. Cutis 1992;50(5):383-6
- Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids – new mechanisms for old drugs. N Engl J Med 2005;353(16):1711-23
- Feldman SR, Fleischer AB Jr, Cooper JZ. New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care. Int J Dermatol 2000;39(1):41-4
- Huang X, Tanojo H, Lenn J, et al. A novel foam vehicle for delivery of topical corticosteroids. J Am Acad Dermatol 2005;53(1 Suppl 1):S26-38
- Ahluwalia A. Topical glucocorticoids and the skin – mechanisms of action: an update. Mediators Inflamm 1998;7(3):183-93
- Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol 1952;19(2):101-2
- Hafezi-Moghadam A, Simoncini T, Yang Z, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002;8(5):473-9
- Pitzalis C, Pipitone N, Perretti M. Regulation of leukocyte-endothelial interactions by glucocorticoids. Ann NY Acad Sci 2002;966(1):108-18
- Ayres PJ, Hooper G. Assessment of the skin penetration properties of different carrier vehicles for topically applied cortisol. Br J Dermatol 1978;99(3):307-17
- Kimball AB, Gold MH, Zib B, Davis MW. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents. J Am Acad Dermatol 2008 Jun 6 [Epub ahead of print]
- Franz TJ, Lehman PA, Feldman SR, Spellman MC. Bioavailability of clobetasol propionate in different vehicles. Skin Pharmacol Appl Skin Physiol 2003;16(4):212-6
- Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006;54(1):1, 15; quiz 16-8
- Gold-von Simson G, Kohn B, Axelrod FB. Cushing syndrome from topical foam steroid use in an adolescent male. Clin Pediatr (Phila) 2006;45(1):97-100
- Guven A, Gulumser O, Ozgen T. Cushing's syndrome and adrenocortical insufficiency caused by topical steroids: misuse or abuse? J Pediatr Endocrinol Metab 2007;20(11):1173-82
- Ohman EM, Rogers S, Meenan FO, McKenna TJ. Adrenal suppression following low-dose topical clobetasol propionate. J R Soc Med 1987;80(7):422-4
- Siklar Z, Bostanci I, Atli O, Dallar Y. An infantile cushing syndrome due to misuse of topical steroid. Pediatr Dermatol 2004;21(5):561-3
- Staughton RC, August PJ. Cushing's syndrome and pituitary-adrenal suppression due to clobetasol propionate. BMJ 1975;2(5968):419-21
- Stoughton RB. Adrenal suppression following low-dose topical clobetasol propionate. J R Soc Med 1988;81(5):308
- Physicians' desk reference: PDR; 1974
- Bergstrom KG, Arambula K, Kimball AB. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003;72(5):407-11
- Lebwohl M, Sherer D, Washenik K, et al. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol 2002;41(5):269-74
- Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 200;7(3):185-92
- World Health Organization. Improving access to quality care in family planning: medical eligibility criteria for contraceptive use. 3rd edition. Geneva: Switzerland; 2003